AI Science Tracker

Machine learning identifies new CYP2C9-inhibiting drugs and drug metabolites

INSERM; CNRS and Université de Paris; Conservatoire National des Arts et Métiers; Université de Lorraine; Nantes Université · 26 Jan 2022 · chemistry

Discovery

Machine learning identifies new CYP2C9-inhibiting drugs and drug metabolites

A structure-, dynamics- and physicochemical-feature machine-learning approach predicted CYP2C9 inhibition and experimentally identified four drugs—vatalanib, piriqualone, ticagrelor and cloperidone—as strong inhibitors, plus sertindole, asapiprant, duvelisib and dasatinib as moderate inhibitors in reported assays. Vatalanib had a reported CYP2C9 inhibition IC50 of 0.067 μM. Separate metabolism assays characterized CYP2C9-produced metabolites for abemaciclib, cloperidone, vatalanib and tarafenacin.

Technology: Machine-learning inhibitor predictors combining CYP2C9 structural/dynamics information with inhibitor physicochemical properties

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: A structure-, dynamics- and physicochemical-feature machine-learning approach predicted CYP2C9 inhibition and experimentally identified four drugs—vatalanib, piriqualone, ticagrelor and cloperidone—as strong inhibitors, plus sertindole, asapiprant, duvelisib and dasatinib as moderate inhibitors in reported assays.
  • Still unknown: Inhibition and metabolite findings are from the reported in vitro systems and do not by themselves establish clinically relevant drug–drug interactions, exposure changes, or patient harm. Reported inhibition strengths are assay-specific; clinical relevance depends on dose, exposure and context and requires pharmacokinetic/clinical assessment.
  • AI role: The authors used machine-learning models to prioritize drug-like compounds for CYP2C9 inhibition testing. Follow-up in vitro assays identified the listed strong and moderate inhibitors; CYP2C9 metabolism assays separately characterized metabolites of four drugs.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/35081108/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 38 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.